Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34Leukemia 15Gastrointestinal Stromal Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Chronic-Phase 7Philadelphia Chromosome 4Leukemia, Myeloid 4Bone Marrow Diseases 4Neoplasms 3Myeloproliferative Disorders 3Hematologic Diseases 3Melanoma 2Hematologic Neoplasms 2Bronchiolitis Obliterans Syndrome 2Blast Crisis 2Synovitis, Pigmented Villonodular 1Recurrence 1Piebaldism 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplastic Processes 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Mastocytosis, Systemic 1Leukemia, Myeloid, Accelerated Phase 1Hypereosinophilic Syndrome 1Glioma 1

Interventions

Brentuximab Vedotin 13fludarabine 8Cyclophosphamide 8Rituximab 6ruxolitinib 5fludarabine phosphate 5Melphalan 5Lenalidomide 5ponatinib 4Dexamethasone 4Busulfan 4Bortezomib 4nilotinib 3Whole-Body Irradiation 3Vincristine 3Prednisone 3Mycophenolic Acid 3Imatinib Mesylate 3Doxorubicin 3Bendamustine Hydrochloride 3Alemtuzumab 3vosaroxin 2pomalidomide 2Tacrolimus 2Sugars 2Stem Cell Transplantation 2Sirolimus 2Ondansetron 2Leukapheresis 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Hematologic Diseases × nilotinib × Clear all
NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02627677 2021-11-26

OPTIC-2L

Takeda

Phase 3 Terminated
44 enrolled 22 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01844765 2021-04-22

DIALOG

Novartis

Phase 2 Completed
59 enrolled 33 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myeloproliferative Disorders, Neoplastic Processes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡